Sexual behavior and HPV infection in British women, by postal questionnaires and telephone interviews† ‡
This epidemiological study was conducted in the London School of Hygiene and Tropical Medicine. The study population was composed of women participating in the ARTISTIC (A Randomized Trial In Screening To Improve Cytology) trial ran in Greater Manchester.
The authors have no conflict of interest to disclose.
Abstract
Sexually transmitted human papillomaviruses (HPVs), most frequently HPV 16, are the primary cause of cervical carcinogenesis. The aim of this study was to evaluate the relationship between sexual behavior and prevalence and acquisition of HPV infection among British women attending regular cervical screening who responded to postal questionnaires and/or telephone interviews. A total of 1,880 women who had been tested for HPV in the ARTISTIC (A Randomized Trial In Screening To Improve Cytology) trial were randomized to three methods of data collection: group 1 (questionnaire including sexual history, no interview), group 2 (questionnaire excluding sexual history, short interview including sexual history), and group 3 (questionnaire and long interview including sexual history in both). Questions on sexual history included age at first sexual intercourse, sexually transmitted diseases, lifetime (total and regular) sexual partners, and number of partners in the last 5 years (total and new). Demographics, reproductive, cervical screening, and smoking history were also collected in questionnaires. The overall participation rate was 35%. There was good agreement (87.4–95.5%) on sexual behavior answers in questionnaires and interviews in women in group 3 and no significant differences between data obtained by questionnaire or interview. Odds ratios (OR) for both HPV prevalence and acquisition increased consistently with increasing numbers of lifetime sexual partners, regular partners, and new partners in the last 5 years (recent partners). No significant association was found for other characteristics investigated. The effect of recent sexual partners on HPV acquisition (OR for 2+ recent partners: 4.4, 95% CI: 1.7–11.2) was stronger than that of earlier (>5 years ago) partners (OR for 2+ earlier partners: 2.2, 95% CI: 0.7–6.7) suggesting that most incident HPV infections are newly acquired rather than recurrent. J. Med. Virol. 83:1238–1246, 2011. © 2011 Wiley-Liss, Inc.
INTRODUCTION
Cervical cancer is the third most common cancer among women worldwide [Ferlay et al., 2010], and is more frequent in many socio-economically deprived populations [Almonte et al., 2008]. Human papillomaviruses (HPVs), most frequently HPV 16, are the primary cause of cervical carcinogenesis [International Agency for Research on Cancer, 1995]. Over 100 HPV types have now been described, including 13 “high-risk” types that are definitively associated with cervical cancer and several more that are probably carcinogenic [International Agency for Research on Cancer, 2007]. The overall prevalence of HPV in cervical cancers worldwide is over 99%, implying the highest attributable fraction ever identified for a specific cause of a major human cancer [Walboomers et al., 1999].
HPV is one of the most common sexually transmitted infections [Bosch et al., 2008]. Most women become infected during their lives, although the majority of the infections are transient and clear within 2 years [Plummer et al., 2007]. HPV genital acquisition is associated with sexual behavior patterns such as early age at first sexual intercourse, number of sexual partners, and sexual behavior of the partner; and certain co-factors (high parity, long-term use of hormonal contraceptives, and cigarette smoking) help in the progression from infection to cancer [Vaccarella et al., 2006; Almonte et al., 2008; Vaccarella et al., 2008].
This study describes sexual behavior patterns in relation to HPV prevalence and acquisition rates among British women who participated in the ARTISTIC trial (A Randomized Trial In Screening To Improve Cytology), which was conducted in Greater Manchester [Kitchener et al., 2006]. In order to compare responses and participation rates, the method of ascertaining sexual behavior was randomized between postal questionnaire, telephone interview, and both.
MATERIALS AND METHODS
The ARTISTIC Trial
In the ARTISTIC trial, 24,510 women aged 20–64 who were attending for routine cervical cytology in four health authorities (Manchester, Salford & Trafford, Wigan, and Stockport) in 2001–2003 were screened with liquid-based cytology (LBC) and HPV testing [Kitchener et al., 2006]. LBC samples were collected and processed using ThinPrep (Hologic, Crawley, UK). Hybrid Capture 2 (hc2; Digene/Qiagen, Crawley, UK) was used to test for high-risk HPV DNA. This nucleic acid microplate chemiluminescent detection assay detects 13 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68). Results were read and calculated on the Digene Microplate Luminometer 2000 (DML 2000; Qiagen) using the hc2 software at the recommended relative light units (RLU) to control ratio of ≥1.0. HPV results were reported independently of cytology.
At entry, women were randomly allocated in a 1:3 ratio to have their HPV results concealed or revealed. Cytologically normal women in the revealed arm who were HPV positive (HPV+) were recalled a year later, and those with persistent HPV were offered colposcopy. Women were invited to a second screening round between 26 and 54 months after entry into the study.
Study Population
A random sample of 1,880 ARTISTIC participants who attended the second screening round (26–54 months after entry) and who had an adequate cytology in the second round was selected. All women had a satisfactory HPV test at entry, and the majority (87%) had adequate HPV tests at the next screening round.
Data Collection
These women were randomized to three methods of obtaining sexual behavior data: postal questionnaire including sexual behavior and no interview (group 1), postal questionnaire excluding sexual history and a short interview including sexual behavior (group 2), and both postal questionnaire and a longer interview containing sexual behavior including a calendar of sexual partners (group 3). All women received an invitation package containing a description of the study, a consent form and a postal questionnaire that included age, current weight and height, marital status, education, smoking, reproductive history (menarche, menopause, parity, and use of hormonal contraceptives), and age at first cervical smear. The questionnaire for groups 1 and 3, which was similar to that used in a previous study in the Manchester area [Deacon et al., 2000], had an additional section with questions on sexual behavior. These included age at first sexual intercourse, ever having a sexual transmitted disease (STD), and number of regular (more than 3 months) and shorter relationships with male sexual partners overall and in the previous 5 years. The interview for groups 2 and 3 included the same sexual behavior questions, so questionnaire and interview responses could be compared for women in group 3. The interview for group 3 also included further details on each relationship (age, duration, and contraceptive method). Additionally, questionnaires and both short and long interviews included three common questions: current weight, current height, and age at first cervical screening so these variables could also be compared in questionnaires and interviews in groups 2 and 3. Short interviews lasted 8 min and long ones 16 min on average and were conducted by a trained research nurse with expertise in conducting telephone interviews for different cancer related studies.
Women were informed in the invitation letter whether they would also be interviewed or would only need to return the questionnaire. All women were asked to give a blood sample for future studies and to sign a consent for their screening records to be reviewed by the investigators. Non-responders were sent a reminder letter 3–10 months later.
Ethical approval was provided by the North West Multicentre Research Ethics Committee (MREC).
Statistical Analysis
To ensure the return of 200 questionnaires in each group, a minimal response rate of 32% was assumed, so invitation packages were sent to 1,880 women.
Non-response and refusal rates were based on all women who were sent a questionnaire. Further analyses were restricted to women who returned both the consent form and questionnaire. Current BMI was calculated in kg/m2 and was categorized in four groups (<18.5, 18.5–24.9, 25–29.9, and ≥30 kg/m2). Kappa statistics were used to compare questionnaire and interview responses of women in group 2 (BMI and age at first cervical smear) and group 3 (BMI, age at first smear, and sexual behavior variables). Analyses of HPV status at the second screening round were restricted to women who had an HPV test result both at entry and at the second screening round 26–54 months later. Age-adjusted odds ratios (AORs) with corresponding 95% confidence intervals (95% CI) for HPV prevalence at the second round (HPV detection at the second round irrespectively of HPV test result in the first round) and for HPV acquisition (HPV detection at round 2 in women who were HPV negative in round 1) were calculated by unconditional logistic regression for single variables, and for the combined effects of new partners in the last 5 years (recent partners) and parnters more than 5 years ago (earlier partners). Two-sided significance levels were calculated using Fisher's exact test or chi-squared tests for trend or heterogeneity. All analyses were carried out using Stata 10.
RESULTS
Of the 1,880 women selected, 661 (34% in group 1, 37% in group 2, and 34% in group 3) agreed to participate (512 at first invitation), 182 (10%) refused, and 1,037 (55%) did not reply to the invitation or reminder. Among 1,037 non-respondents, two women died, 3 withdrew from the ARTISTIC trial, and 163 (16%) changed address during the invitation process (information from the trial coordination office or by returned mail). There were no significant differences between randomization groups (group 1: questionnaire; group 2: questionnaire excluding sexual history, short interview; group 3: questionnaire, longer interview) in response, refusal, and non-response rates. Nine women in group 2 and 14 in group 3 returned the questionnaire but were not interviewed. Table I shows overall participation rates in this study and numbers in each group by age, allocated screening protocol (HPV result revealed or concealed), cytology at entry, and HPV status at entry and at the second screening round in the ARTISTIC trial. Participation rates ranged from 29% to 39%, with a lower rate among women aged under 35 (P = 0.03) and those who had been randomized in the ARTISTIC trial to have their HPV results concealed (P = 0.01). Among women who responded there were no significant between-group differences for any of the screening results shown in Table I.
Group 1 | Group 2 | Group 3 | Participants | All invited women | Participation rate (%) | |||||
---|---|---|---|---|---|---|---|---|---|---|
No. | % | No. | % | No. | % | No. | % | |||
Total | 215 | 100 | 233 | 100 | 213 | 100 | 661 | 100 | 1,880 | 35.2 |
Age at entry in the ARTISTIC Trial | ||||||||||
20–24 | 23 | 10.7 | 16 | 6.9 | 18 | 8.5 | 57 | 8.6 | 191 | 29.8 |
25–34 | 42 | 19.5 | 57 | 24.5 | 41 | 19.3 | 140 | 21.2 | 459 | 30.5 |
35–44 | 67 | 31.2 | 77 | 33.1 | 71 | 33.3 | 215 | 32.5 | 562 | 38.3 |
45–54 | 47 | 21.9 | 52 | 22.3 | 51 | 23.9 | 150 | 22.7 | 407 | 36.9 |
55–64 | 36 | 16.7 | 31 | 13.3 | 32 | 15.0 | 99 | 15.0 | 261 | 37.9 |
P = 0.03 (4 df) | ||||||||||
Allocated screening protocol in the ARTISTIC Trial | ||||||||||
HPV revealed | 181 | 84.2 | 174 | 74.7 | 160 | 75.1 | 515 | 77.9 | 1,399 | 36.8 |
HPV concealed | 34 | 15.8 | 59 | 25.3 | 53 | 24.9 | 146 | 22.1 | 481 | 30.4 |
P = 0.01 (1 df) | ||||||||||
Cytology at entry in the ARTISTIC Trial | ||||||||||
Negative | 185 | 86.1 | 206 | 88.4 | 181 | 85.0 | 572 | 86.5 | 1,598 | 35.8 |
Borderline/mild | 22 | 10.2 | 20 | 8.6 | 21 | 9.9 | 63 | 9.5 | 216 | 29.2 |
Moderate/worse | 8 | 3.7 | 7 | 3.0 | 11 | 5.2 | 26 | 3.9 | 66 | 39.4 |
P = 0.12 (2 df) | ||||||||||
HPV testing in the ARTISTIC Trial | ||||||||||
At entry | ||||||||||
Negative | 181 | 84.2 | 195 | 83.7 | 178 | 83.6 | 554 | 83.8 | 1 567 | 35.4 |
Positive | 34 | 15.8 | 38 | 16.3 | 35 | 16.4 | 107 | 16.2 | 313 | 34.2 |
P = 0.69 (1 df) | ||||||||||
At second screening round | ||||||||||
Negative | 167 | 77.7 | 189 | 81.1 | 162 | 76.1 | 518 | 78.4 | 1,419 | 36.5 |
Positive | 17 | 7.9 | 18 | 7.7 | 19 | 8.9 | 54 | 8.2 | 151 | 35.8 |
Not done | 31 | 14.4 | 26 | 11.2 | 32 | 15.0 | 89 | 13.5 | 310 | 28.7 |
P = 0.03 (2 df) | ||||||||||
At entry/second screening round | ||||||||||
Neg/Neg | 147 | 68.4 | 165 | 70.8 | 145 | 68.1 | 457 | 69.1 | 1,257 | 36.4 |
Neg/Pos | 11 | 5.1 | 11 | 4.7 | 10 | 4.7 | 32 | 4.8 | 82 | 39.0 |
Pos/Neg | 20 | 9.3 | 24 | 10.3 | 17 | 8.0 | 61 | 9.2 | 162 | 37.7 |
Pos/Pos | 6 | 2.8 | 7 | 3.0 | 9 | 4.2 | 22 | 3.3 | 69 | 31.9 |
Neg/no test | 23 | 10.7 | 19 | 8.2 | 23 | 10.8 | 65 | 9.8 | 228 | 28.5 |
Pos/no test | 8 | 3.7 | 7 | 3.0 | 9 | 4.2 | 24 | 3.6 | 82 | 29.3 |
P = 0.17 (5 df) |
- Group 1: Questionnaire (included sexual behavior).
- Group 2: Questionnaire (without sexual behavior) and short interview (with sexual behavior).
- Group 3: Questionnaire and long interview (both included sexual behavior).
Similarly, there were no statistically significant between-group differences for any variables not related to sexual behavior collected in questionnaires (Supplementary Table I), therefore these data were pooled and analyze for all women (three groups). Age at second screening round was associated with both HPV acquisition and HPV prevalence, while marital status, ever been pregnant, menopausal status and ever used hormonal contraceptives were associated with HPV prevalence at second round (Table II). No associations remained significant after adjusting for age at second round (AORs: 0.6; 95% CI: 0.3–1.1) for being married or cohabiting 0.9 (95% CI: 0.4–1.8) for ever been pregnant, 1.4 (95% CI: 0.4–4.6) for being menopausal, and 3.9 (95% CI: 0.9–17.5) for ever use of hormonal contraceptives.
HPV prevalence at second screening rounda | HPV acquisition at second screening roundb | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
HPV neg | HPV pos | P (df) | HPV neg | HPV pos | P (df) | |||||
No. | % | No. | % | No. | % | No. | % | |||
Age at second screening round | ||||||||||
20–24 | 10 | 62.5 | 6 | 37.5 | <0.001 (5) | 4 | 57.1 | 3 | 42.9 | <0.001 (5) |
25–34 | 85 | 80.2 | 21 | 19.8 | 66 | 85.7 | 11 | 14.3 | ||
35–44 | 165 | 93.8 | 11 | 6.3 | 145 | 96.0 | 6 | 4.0 | ||
45–54 | 145 | 95.4 | 7 | 4.6 | 135 | 97.1 | 4 | 2.9 | ||
55–64 | 98 | 95.2 | 5 | 4.9 | 93 | 94.9 | 5 | 5.1 | ||
65+ | 15 | 79.0 | 4 | 21.1 | 14 | 82.4 | 3 | 17.7 | ||
Being married/cohabiting | ||||||||||
Yes | 396 | 92.3 | 33 | 7.7 | 0.01 (1) | 359 | 94.5 | 21 | 5.5 | 0.08 (1) |
No | 121 | 85.2 | 21 | 14.8 | 97 | 89.8 | 11 | 10.2 | ||
Age when education completed | ||||||||||
<18 | 271 | 90.6 | 28 | 9.4 | 0.98 (1) | 238 | 92.6 | 19 | 7.4 | 0.33 (1) |
18 | 244 | 90.7 | 25 | 9.3 | 218 | 94.8 | 12 | 5.2 | ||
Menarche | ||||||||||
<12 | 81 | 85.3 | 14 | 14.7 | 0.06 (1) | 71 | 92.2 | 6 | 7.8 | 0.65 (1) |
12+ | 433 | 91.5 | 40 | 8.5 | 382 | 93.6 | 26 | 6.4 | ||
Ever pregnant | ||||||||||
Yes | 425 | 91.8 | 38 | 8.2 | 0.03 (1) | 382 | 93.9 | 25 | 6.2 | 0.47 (1) |
No | 83 | 84.7 | 15 | 15.3 | 65 | 91.6 | 6 | 8.5 | ||
No. alive births | ||||||||||
0 | 25 | 86.2 | 4 | 13.8 | 0.18 (2) | 22 | 91.7 | 2 | 8.3 | 0.33 (2) |
1–2 | 299 | 93.4 | 21 | 6.6 | 272 | 95.1 | 14 | 4.9 | ||
3+ | 107 | 89.2 | 13 | 10.8 | 94 | 91.3 | 9 | 8.7 | ||
Menopausal status | ||||||||||
Menopausal | 200 | 93.9 | 13 | 6.1 | 0.04 (1) | 183 | 95.3 | 9 | 4.7 | 0.18 (1) |
Pre-menopausal | 317 | 88.6 | 41 | 11.5 | 273 | 92.2 | 23 | 7.8 | ||
Ever used hormonal contraceptives | ||||||||||
Yes | 448 | 89.6 | 52 | 10.4 | 0.04 (1) | 393 | 92.9 | 30 | 7.1 | 0.22 (1) |
No | 70 | 97.2 | 2 | 2.8 | 64 | 97.0 | 2 | 3.0 | ||
Age at first smear | ||||||||||
<20 | 127 | 87.0 | 19 | 13.0 | 0.14 (1) | 105 | 91.3 | 10 | 8.7 | 0.38 (1) |
20+ | 288 | 91.4 | 27 | 8.6 | 257 | 93.8 | 17 | 6.2 | ||
Ever smoker | ||||||||||
Yes | 238 | 90.2 | 26 | 9.9 | 0.76 (1) | 207 | 92.8 | 16 | 7.2 | 0.61 (1) |
No | 280 | 90.9 | 28 | 9.1 | 250 | 94.0 | 16 | 6.0 |
- a HPV prevalence at second round: HPV detection at round 2 irrespectively of HPV test result at round 1.
- b HPV acquisition at second round: HPV detection at round 2 in women HPV negative at round 1.
Table III shows responses to questions on sexual behavior from questionnaires for groups 1 and 3, from interviews for groups 2 and 3, and for all women (questionnaire data in groups 1 and 3, interview data in group 2). The only statistically significant difference was in the proportion of women reporting first intercourse at age 20 or later, which was higher in group 2 (short interview) than in group 3 (long interview, 29.2% vs. 19.1%; P = 0.02). The right-hand part of Table III shows percentage agreement (exact and within one category) on questionnaire and interview responses to these questions by women in group 3. There was good agreement (87.4–95.9% exact, 99.5–100% within one category) for all questions. A similar analysis for BMI and age at first smear also showed good agreement between responses in questionnaires and interviews (agreement for current BMI: 92.2% in group 2 and 90.4% in group 3 and for age at first smear: 85.3% in group 2 and 81.3% in group 3, Supplementary Table II).
Between group | Group 1 questionnaires | Group 2 interviews | Group 3 questionnaires | All women | Group 3 interviews | Group 3: questionnaires vs. interviews | ||||
---|---|---|---|---|---|---|---|---|---|---|
P (4 df) | No. (%) | No. (%) | No. (%) | No. (%) | No. (%) | Exact agreement | ±1 Category | |||
% | kappa | % | kappa | |||||||
Total | 215 (100) | 224 (100) | 213 (100) | 652 (100) | 199 (100) | |||||
Age at first sexual intercourse | 0.04 | |||||||||
<17 | 74 (34.6) | 60 (26.9 | 74 (35.1) | 208 (32.1) | 71 (35.7) | 87.4 | 0.80 | 100 | 1.0 | |
17–19 | 98 (45.8) | 98 (44.0) | 99 (46.9) | 295 (45.5) | 90 (45.2) | |||||
20+ | 42 (19.6) | 65 (29.2) | 38 (18.0) | 145 (22.4) | 38 (19.1) | |||||
Not answered | 1 | 1 | 2 | 4 | — | |||||
Ever having STDs | 0.41 | |||||||||
None | 151 (75.9) | 161 (81.7) | 151 (77.4) | 463 (71.1) | 157 (80.1) | 88.8 | 0.68 | |||
Any specifieda | 30 (15.1) | 25 (12.7) | 33 (16.9) | 88 (13.5) | 30 (15.3) | |||||
Other unspecifieda | 18 (9.1) | 11 (5.6) | 11 (5.6) | 40 (15.4) | 9 (4.6) | |||||
Not answered | 16 | 27 | 18 | 61 | 3 | |||||
No. lifetime sexual partners | 0.55 | |||||||||
0–1 | 54 (25.1) | 54 (24.4) | 41 (19.3) | 149 (23.0) | 41 (20.8) | 94.4 | 0.91 | 100 | 1.0 | |
2–4 | 71 (33.0) | 70 (31.7) | 68 (32.1) | 209 (32.3) | 63 (32.0) | |||||
5+ | 90 (41.9) | 97 (43.9) | 103 (48.6) | 290 (44.8) | 93 (47.2) | |||||
Not answered | 0 | 3 | 1 | 4 | 2 | |||||
No. lifetime regular sexual partnersb | 0.56 | |||||||||
0–1 | 61 (29.2) | 64 (28.8) | 51 (25.1) | 176 (27.8) | 52 (26.3) | 89.0 | 0.83 | 99.5 | 0.97 | |
2–4 | 95 (45.5) | 89 (40.1) | 92 (45.3) | 276 (43.5) | 89 (45.0) | |||||
5+ | 53 (25.4) | 69 (31.1) | 60 (29.6) | 182 (28.7) | 57 (28.8) | |||||
Not answered | 6 | 2 | 10 | 18 | 1 | |||||
No. sexual partners in the last 5 years | 0.74 | |||||||||
0–1 | 170 (80.6) | 184 (82.5) | 170 (81.3) | 524 (81.5) | 162 (81.8) | 95.9 | 0.87 | 99.5 | 0.94 | |
2–4 | 31 (14.7) | 32 (14.4) | 27 (12.9) | 90 (14.0) | 26 (13.1) | |||||
5+ | 10 (4.7) | 7 (3.1) | 12 (5.7) | 29 (4.5) | 10 (5.1) | |||||
Not answered | 4 | 1 | 4 | 9 | 1 | |||||
No. new sexual partners in the last 5 years (recent partners) | 0.45 | |||||||||
0–1 | 176 (85.9) | 198 (88.8) | 171 (84.7) | 545 (86.5) | 171 (86.4) | 94.7 | 0.79 | 99.5% | 0.94 | |
2–4 | 20 (9.8) | 21 (9.4) | 21 (10.4) | 62 (9.8) | 18 (9.1) | |||||
5+ | 9 (4.4) | 4 (1.8) | 10 (5.0) | 23 (3.7) | 9 (4.6) | |||||
Not answered | 10 | 1 | 11 | 22 | 1 |
- a Specified STDs: trichomonas, genital warts, herpes, gonhorrea and chlamydia. Unspecified STDs: any other infection excluding thrush.
- b Regular sexual partners defined as relationships lasting 3 or more months.
Table IV shows age-specific rates for HPV prevalence at the next screening round and for HPV acquisition (HPV positive at round 2 in women who were HPV negative at entry) for all women with an HPV test at the second screening round. Table IV shows age-adjusted HPV prevalence and acquisition ORs for each sexual history question, and the multivariate ORs including age, number of earlier sexual partners and number of earlier partners. ORs for both prevalence and acquisition increased consistently with increasing number of lifetime sexual partners and lifetime regular partners. For HPV acquisition the effect of recent sexual partners (OR for 2+ recent partners: 4.4, 95% CI: 1.7–11.2) appeared to be stronger than that of earlier partners (OR for 2+ earlier partners: 2.2, 95% CI: 0.7–6.7).
HPV prevalence at second round | HPV acquisition at second round (women HPV neg at entry) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
All women | No. (%) HPV pos | Age-adjusted OR | 95% CI | Multivariate OR | 95% CI | HPV neg at entry | No. (%) HPV+ | Age-adjusted OR | 95% CI | Multivariate OR | 95% CI | |
Age at second screening round | ||||||||||||
20–24 | 15 | 5 (33.3) | 1.4 | 0.4–4.9 | 7 | 3 (42.9) | 3.2 | 0.6–17.9 | ||||
25–34 | 104 | 20 (19.2) | 1.0 | 77 | 11 (14.3) | 1.0 | ||||||
35–44 | 174 | 11 (6.3) | 0.4 | 0.2–0.9 | 150 | 6 (4.0) | 0.4 | 0.1–1.1 | ||||
45–54 | 151 | 7 (4.6) | 0.3 | 0.1–0.8 | 138 | 4 (2.9) | 0.3 | 0.09–1.2 | ||||
55–64 | 103 | 5 (4.9) | 0.4 | 0.1–1.3 | 98 | 5 (5.1) | 0.8 | 0.2–2.8 | ||||
65+ | 19 | 4 (21.1) | 2.1 | 0.6–8.1 | 17 | 3 (17.7) | 3.2 | 0.6–15.4 | ||||
Age at first sexual intercourse | ||||||||||||
≤16 | 175 | 22 (12.6) | 1.0 | 148 | 14 (9.5) | 1.0 | ||||||
17–19 | 259 | 19 (7.3) | 0.7 | 0.4–1.5 | 213 | 9 (4.2) | 0.6 | 0.2–1.6 | ||||
20+ | 128 | 11 (8.6) | 0.9 | 0.4–2.2 | 122 | 9 (7.4) | 1.0 | 0.3–2.9 | ||||
Ever having STDs | ||||||||||||
None | 400 | 34 (8.5) | 1.0 | 354 | 21 (5.9) | 1.0 | ||||||
Specifieda | 77 | 14 (18.2) | 2.0 | 1.0–4.2 | 59 | 9 (15.3) | 2.5 | 1.0–6.1 | ||||
Unspecifieda | 88 | 4 (4.6) | 0.5 | 0.2–1.6 | 73 | 2 (2.7) | 0.5 | 0.1–2.2 | ||||
No. of lifetime sexual partners | ||||||||||||
0–1 | 141 | 6 (4.3) | 1.0 | 137 | 4 (2.9) | 1.0 | ||||||
2–4 | 178 | 11 (6.2) | 1.5 | 0.5–4.2 | 155 | 7 (4.5) | 1.8 | 0.5–6.8 | ||||
5+ | 246 | 35 (14.2) | 3.4 | 1.2–9.6 | 194 | 21 (10.8) | 5.0 | 1.4–18.7 | ||||
No. of lifetime regular partners | ||||||||||||
0–1 | 164 | 6 (3.7) | 1.0 | 154 | 3 (2.0) | 1.0 | ||||||
2–4 | 231 | 22 (9.5) | 2.5 | 0.9–6.7 | 194 | 12 (6.2) | 3.8 | 0.9–14.9 | ||||
5+ | 155 | 22 (14.2) | 3.6 | 1.3–10.3 | 124 | 15 (12.1) | 8.1 | 1.9–34.2 | ||||
No. of sexual partners >5 years ago (earlier partners) | ||||||||||||
0–1 | 150 | 8 (5.3) | 1.0 | 1.0 | 143 | 5 (3.5) | 1.0 | 1.0 | ||||
2–4 | 183 | 13 (7.1) | 1.4 | 0.5–3.6 | 1.7 | 0.7–4.2b | 157 | 8 (5.1) | 1.7 | 0.5–5.8 | 2.2 | 0.7–6.7b |
5+ | 227 | 31 (13.7) | 2.4 | 0.9–6.3 | 182 | 19 (10.4) | 3.6 | 1.1–12.1 | ||||
No. of new partners in last 5 years (recent partners) | ||||||||||||
0–1 | 492 | 33 (6.7) | 1.0 | 1.0 | 435 | 20 (4.6) | 1.0 | 1.0 | ||||
2–4 | 52 | 12 (23.1) | 2.6 | 1.1–5.9 | 3.1 | 1.5–6.5b | 37 | 7 (18.9) | 3.5 | 1.2–10.1 | 4.4 | 1.7–11.2b |
5+ | 16 | 7 (43.8) | 6.0 | 1.9–19.3 | 10 | 5 (50.0) | 12.0 | 2.6–55.8 |
- Age-adjusted ORs for each sexual variable, and multivariate analysis fitting age, new partners in last 5 years and partners over 5 years ago.
- a Specified STDs: trichomonas, genital warts, herpes, gonorrhea, chlamydia. Unspecified STDs: any other infection excluding thrush.
- b ORs compared two or more sexual partners with less than two partners.
Table V tabulates the number of sexual partners over lifetime and in the last 5 years according to age at first sexual intercourse and year of birth. There were marked changes in sexual behavior between women born before 1940 and those born in 1970–1979. The percentage with more than one lifetime sexual partner increased from 50% (10/20) to 94% (125/133) (P for trend <0.001) and the percentage reporting a sexual relationship before age 17 increased from 0% (0/20) to 44% (58/133; P for trend <0.001). Similar cohort trends were observed for number of sexual partners in the last 5 years.
Age at first sexual intercourse | Year of birth | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
<1940 | 1940–1949 | 1950–1959 | 1960–1969 | 1970–1979 | |||||||||||
No. of lifetime sexual partners (n = 625)a | |||||||||||||||
0–1 | 2–4 | 5+ | 0–1 | 2–4 | 5+ | 0–1 | 2–4 | 5+ | 0–1 | 2–4 | 5+ | 0–1 | 2–4 | 5+ | |
≤16 | 5 | 6 | 4 | 3 | 18 | 20 | 2 | 19 | 54 | 1 | 9 | 48 | |||
17–19 | 1 | 5 | 18 | 30 | 5 | 24 | 23 | 37 | 11 | 35 | 43 | 6 | 16 | 38 | |
20+ | 9 | 4 | 1 | 34 | 10 | 3 | 21 | 12 | 5 | 11 | 12 | 7 | 1 | 7 | 7 |
No. of sexual partners in the last five years (n = 618)a | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0–1 | 2–4 | 5+ | 0–1 | 2–4 | 5+ | 0–1 | 2–4 | 5+ | 0–1 | 2–4 | 5+ | 0–1 | 2–4 | 5+ | |
≤16 | 14 | 32 | 7 | 1 | 58 | 12 | 5 | 33 | 18 | 6 | |||||
17–19 | 6 | 49 | 2 | 74 | 7 | 2 | 79 | 10 | 39 | 14 | 7 | ||||
20+ | 12 | 2 | 45 | 1 | 36 | 2 | 27 | 3 | 12 | 3 |
- a Analysis included all women born before 1980 who answered these questions irrespectively of HPV testing at second round.
Table VI shows the number of lifetime sexual partners by age, reported by women participating in a large National Survey of Sexual Attitudes and Lifestyles (NATSAL) conducted in 2000 [Johnson et al., 2001] and in women in the current study who were aged 17–45 in 2000. Lifetime number of sexual partners up to 2000 was estimated as the number of partners more than 5 years before the survey, as 89% of questionnaires/interviews were done between 2004 and 2006.) The distributions of the number of lifetime sexual partners in women ≥25 years old were similar in both studies (average number of sexual partners 7.1 in the current study and 6.9 in NATSAL 2000) but in women under age 25 a substantially larger proportion of respondents reported ≥5 sexual partners (63%) than in NATSAL. This presumably reflects, a tendency for women with several partners to attend for screening earlier.
Number of lifetime male sexual partnersa | This study | National Survey of Sexual Attitudes and Lifestyles | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Age in year 2000 (n = 436) | Age in year 2000 (n = 6399) | |||||||||||
17–24 | 25–34 | 35–44 | All ages | 16–24 | 25–34 | 35–44 | All ages | |||||
No. | % | No. | % | No. | % | No. | % | % | % | % | % | |
0 | 0 | 0.0 | 2 | 1.2 | 2 | 1.0 | 4 | 0.9 | 17.7 | 0.9 | 0.9 | 5.3 |
1 | 9 | 12.3 | 16 | 9.5 | 37 | 19.0 | 62 | 14.2 | 18.1 | 16.2 | 20.8 | 18.3 |
2 | 5 | 6.9 | 14 | 8.3 | 23 | 11.8 | 42 | 9.6 | 11.1 | 10.8 | 10.9 | 10.9 |
3–4 | 13 | 17.8 | 39 | 23.2 | 48 | 24.6 | 100 | 22.9 | 17.1 | 19.7 | 21.5 | 19.6 |
5–9 | 25 | 34.3 | 54 | 32.1 | 47 | 24.1 | 126 | 28.9 | 21.5 | 29.8 | 26.6 | 26.5 |
10+ | 21 | 28.8 | 43 | 25.6 | 38 | 19.5 | 102 | 23.4 | 14.6 | 22.7 | 19.4 | 19.4 |
Total | 73 | 100.0 | 168 | 100.0 | 195 | 100.0 | 436 | 100.0 | ||||
Mean no. of partners | 12.0 | 7.7 | 5.6 | 7.5 | 5.0 | 7.3 | 6.8 | 6.5 |
- * Adapted from Johnson et al. [2001].
- a No. of lifetime sexual partners in year 2000 = No. of lifetime sexual partners − No. of new partners in the last 5 years.
DISCUSSION
Cervical cancer is the third most common cancer among women worldwide [Ferlay et al., 2010], with the highest attributable fraction ever identified for a specific cause of a major human cancer [Walboomers et al., 1999]. HPV 16 and 18 are the most frequent types associated with cervical cancer and two prophylactic vaccines against these high-risk types are available and are being used to vaccinate young women (mostly adolescents) in several countries. Most HPV infections are no longer detectable 2 years later [Plummer et al., 2007; Rodriguez et al., 2008], but it is unknown whether HPV in a woman who was HPV negative at a previous test is newly acquired or it is a recurring a latent infection. HPV testing may soon replace cytology as the primary cervical screening test, at least in older women, and the significance of transient and persistent infections is an important aspect of the natural history of HPV infection and cervical neoplasia in relation to screening policy and clinical management. Viral latency is also relevant to the effectiveness of HPV vaccination in older women, many of whom have cleared a previous HPV infection. This study describes the sexual behavior patterns in relation to HPV prevalence and HPV acquisition rates in a sample of British women attending regular cervical screening.
The multiple regression results suggest that most incident infections are newly acquired, as HPV acquisition was determined mainly by the number of new sexual partners in the last 5 years (OR for 2+: 4.4, 95% CI: 1.7–11.2). The smaller and non-significant effect of earlier partners (OR for 2+: 2.2, 95% CI: 0.7–6.7) may be attributable to residual confounding, as the partner of a woman who has had multiple partners is more likely to have had several partners himself. A weak association of lifetime number of sexual partners with HPV acquisition after adjusting for the effect of recent partners has been seen in a number of studies [Moscicki et al., 2001; Velicer et al., 2009]. Several studies have shown increased risk of new HPV infection in young women who started a new sexual relationship [Ho et al., 1998; Moscicki et al., 2001; Giuliano et al., 2002; Winer et al., 2006; Oh et al., 2008; Nielsen et al., 2009; Velicer et al., 2009]. A study in young women in the US [Moscicki et al., 2001] reported that 55% of uninfected women under age 22 years attending family planning clinics acquired an HPV infection within 3 years; the risk increasing with numbers of new partners. Data on HPV acquisition in older women are sparse, and the reason for the high HPV prevalence seen in older women in many developing countries [Herrero et al., 2000; Lazcano-Ponce et al., 2001; Molano et al., 2002; Ferreccio et al., 2004] is not known. Twenty-seven (10.0%) of the women aged over 45 in this study reported one or more new partners in the last 5 years and 11.1% (3/27) of these had a new HPV infection at the second round, compared with 3.7% (9/243) of those with no new partner.
The results of this study are limited because it was not powered to evaluate the association between sexual activity and HPV status; instead the sample size was fixed to a minimum of 200 women targeted by each method of data collection assuming a minimal response rate of 30%. However, these limited data clearly suggest that HPV is often recently acquired rather than persistent or recurrent even in older women.
Postal questionnaires are less expensive and perhaps less intrusive than personal interviews, but they may provide less reliable information on sensitive sexual behavior data. The comparison of responses on sexual behavior showed no substantial differences between British women returning postal questionnaires and those interviewed by telephone, or between questionnaire and interview responses by women who provided both. Among women aged 25 or older the distribution of sexual partners observed in this study was similar to the results of Natsal 2000 [Johnson et al., 2001], which was based on a national random sample of women interviewed at home (Table VI). Similarly, the patterns of sexual behavior reported by South Korean students returning a postal questionnaire [Shin et al., 2004] were similar to those obtained by a household interview in The National Health and Nutrition South Korea Survey [Oh et al., 2008]. A recent study conducted in the US suggests that reporting of potentially sensitive information such as very early sexual intercourse in women and late first intercourse in men is increased when telephone interviews are automated rather than conducted by an interviewer [Turner et al., 2009].
For both scientific and practical reasons it thus appears that personal interviews, at least in this field, have no advantages over more impersonal and less expensive alternatives. Postal questionnaires or automated telephone interviews are easier and less expensive to administer and code consistently than personal interviews. This is an important finding, as large samples will need to be surveyed to monitor future changes in sexual behavior among adolescents (age 12–13) who are now being vaccinated against HPV and will not begin cervical screening cervical screening (age 25) for more than a decade later.